Full-Time

Machine Learning Scientist

Agentic data pipelines

Updated on 8/1/2026

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$148k - $210k/yr

Boston, MA, USA + 1 more

More locations: Bristol, UK

Remote

Remote within the US or UK; on-site work is available in Boston or Bristol.

Category
AI & Machine Learning (1)
Required Skills
LLM
Claude
Kubernetes
Python
Data Science
Machine Learning
OpenAI
ETL
Docker
AWS

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A Master's or PhD in a computational STEM field, or equivalent industry experience.
  • Strong Python engineering skills, including experience building and maintaining production-quality software.
  • Hands-on experience with large language model APIs such as Claude or GPT and agentic patterns such as tool use, orchestration, and multi-step reasoning.
  • Familiarity with biomedical or chemical data sources and formats such as PDB, UniProt, ChEMBL, SDF/MOL, FASTA, or similar.
  • Comfort with data-engineering fundamentals, including ETL design, data validation, and working with structured and unstructured data at scale.
Responsibilities
  • Design, build, and maintain agentic systems for automated data acquisition from public and proprietary biomedical data sources.
  • Develop large-language-model-based pipelines for data cleaning, normalization, and formatting across diverse data modalities, including molecular, genomic, clinical, and literature data.
  • Implement automated quality-control workflows that detect anomalies, flag inconsistencies, and enforce data standards.
  • Evaluate and iterate on agent architectures, prompting strategies, and tool-use patterns to improve reliability and throughput.
  • Collaborate with machine-learning scientists on the Enchant team to understand data requirements and translate them into scalable acquisition and processing systems.
  • Monitor and maintain data pipelines in production, diagnose failures, and improve robustness over time.
  • Document data provenance, processing decisions, and quality metrics to support reproducibility and auditing.
Desired Qualifications
  • Experience with agent orchestration frameworks.
  • Familiarity with cloud infrastructure and workflow orchestration, including AWS, Docker, or Kubernetes.
  • Knowledge of multimodal biomedical data spanning small molecules, proteins, assays, images, omics, or clinical records.
  • Experience with large-scale dataset construction or curation for machine-learning model training.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda collaboration on February 9, 2026, offers up to $1.7B in milestones.
  • Over $100M oversubscribed funding in November 2025 from Sequoia and Regeneron.
  • Pipeline advances IAM1363 to Phase 1b with positive ESMO safety data.

What critics are saying

  • Exscientia’s EXS-21546 captures HER2 market with Phase 1 data in 6-12 months.
  • Insilico’s ISM1363 HER2 degrader enters Phase 1, outperforming IAM1363 in 12-18 months.
  • IAM1363 Phase 1 fails safety due to EGFR toxicity, halting in 3-9 months.

What makes Iambic Therapeutics unique

  • NeuralPLexer outperforms in predicting protein-ligand complexes per Nature Machine Intelligence.
  • IAM1363 shows 1000-fold HER2 selectivity over EGFR with CNS penetrance in Phase 1.
  • Weekly design-make-test cycles via Enchant and automated labs accelerate discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
intelligence360
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

entArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.